Ketamine: all studies (page 325) - The Consciousness Library

The renaissance of research on psychedelics in child and adolescent psychopharmacology

Child and Adolescent Psychiatry and Mental Health March 13, 2026 Marc-Antoine Crocq, Philippe Auby

Aims The recent regulatory approval of esketamine in adults heralded the renaissance of research into psychedelic compounds. However, the relevance of this resurgence for children and adolescents remains unclear. This review examines the rationale for investigating psychedelics in pediatric psychopharmacology. Methods We reviewed recent literature, regulatory documents, and clinical trial...

DOI: 10.1186/s13034-026-01069-6 Full text LSD MDMA Psilocybin Esketamine +5

Divergent Mechanisms of Antidepressant Efficacy: A Unified Computational Comparison of Synaptogenesis, Stabilization, and Tonic Inhibition in a Model of Depression.

Cureus March 2026 Ngo Cheung

Major depressive disorder (MDD) is increasingly viewed as a disorder of impaired neural plasticity, yet the mechanisms underlying diverse antidepressant classes - glutamatergic (e.g., ketamine), monoaminergic (e.g., selective serotonin reuptake inhibitors (SSRIs)), and GABAergic (e.g., neurosteroids) - remain incompletely integrated. The objective of this study was to extend a...

DOI: 10.7759/cureus.105040 Full text Depression Ketamine Computational psychiatry Neurosteroid

Hallucinogen use in the United States, 2021-2023: Diverging trends and subgroup patterns.

Drug and Alcohol Dependence Reports March 1, 2026 Jing-Jer Chen, Carla J. Berg, Y Tony Yang 1 citation

While interest in the therapeutic and recreational use of hallucinogens has increased, national surveillance often reports use in aggregate, potentially masking shifting trends among pharmacologically distinct substances. This study assessed trends in specific hallucinogens from 2021 to 2023 and identified correlates of use, with particular attention to subgroup patterns in populations commonly...

DOI: 10.1016/j.dadr.2026.100410 Full text Ketamine LSD Epidemiology Hallucinogens +2

Oxidative Stress in Treatment-Resistant and Refractory Depression: A Hidden Therapeutic Target?

Molecular Neurobiology February 5, 2026 Zofia Winczewska, Wiesław Jerzy Cubała, Piotr Radziwiłłowicz et al. 5 citations

Treatment-resistant depression (TRD) poses a serious challenge to psychopharmacology, as many patients do not achieve remission despite available therapies. The persistence and recurrence of the disease in the absence of response to antidepressant treatment highlight the complex and multifactorial nature of the disease, including the dysregulation of biological processes such as oxidative...

DOI: 10.1007/s12035-026-05715-0 Full text Ketamine Treatment-resistant depression Antioxidants Oxidative stress +1

Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments.

Journal of the Royal Society of New Zealand February 1, 2026 Neil McNaughton, Shabah M. Shadli, Ben Beaglehole et al.

The neurotic disorders (e.g., depression, dysthymia, generalized anxiety disorder, panic disorder, agoraphobia, social anxiety, post-traumatic stress disorder, and obsessive-compulsive disorder) are costly and difficult to treat. Diagnosis is based on symptoms not biological causes. Here, we summarize New Zealand-based work developing EEG biomarkers and novel treatments. Working at the...

DOI: 10.1002/snz2.70002 Full text Depression Ketamine EEG Anxiety biomarker +1

Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance.

Neurologic Clinics February 1, 2026 Mina Ansari, Sophie I Elliott, Sophie E Holmes et al. 1 citation

The development of novel, rapid-acting treatments and the resurgence of interest in the therapeutic potential of psychedelic-like compounds has stimulated excitement and enthusiasm within the pharmaceutical industry, and provided new hope for millions of individuals suffering with mental illness such as major depressive disorder and post-traumatic stress disorder. This review summarizes the...

DOI: 10.1016/j.ncl.2025.08.009 Full text Ketamine MDMA Psilocybin Psychedelic therapy +6

Atypical Manifestation of Postoperative Delirium After an Opioid-free Prostatectomy: A Case Study Report.

Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses January 28, 2026 Karina Bridges, Ionela Morosanu, Lilian Njoki et al.

At a clinical research hospital, the Department of Perioperative Services has recently implemented an opioid-free anesthesia protocol for selected patients undergoing robotic-assisted prostatectomy. This protocol incorporates intraoperative infusions of ketamine, lidocaine, and magnesium as part of a multimodal analgesic strategy. The present case report describes an unusual occurrence of...

DOI: 10.1016/j.jopan.2025.11.008 Full text Ketamine Case reports Opioid-free anesthesia Patient safety +2

PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION

International Journal of Innovative Technologies in Social Science January 28, 2026 Łukasz Deska, Cezary Kosmecki, Dawid Głaz et al.

This manuscript comprehensively reviews psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression. It aims to synthesize current understanding regarding its mechanisms, efficacy, safety, costs, and accessibility, comparing it with conventional antidepressant and ketamine treatments. The methodology involved a narrative synthesis of academic literature, drawing...

DOI: 10.31435/ijitss.1(49).2026.4711 Psilocybin Major depressive disorder Treatment-resistant depression Ketamine +9

Astroglia and depression: A Gliocentric perspective from rodent models to therapeutic insights.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 27, 2026 Rhea Subba, Surendar Ellappan, Sugato Banerjee et al.

Major depressive disorder (MDD) is a debilitating neuropsychiatric condition that affects individuals worldwide. While neuronal deficits have long been recognized in depression pathogenesis, astroglia are increasingly gaining attention. Astroglia are essential for maintaining brain homeostasis, and regulate neurotransmission, neuroinflammation, and metabolic processes that are disrupted in MDD....

DOI: 10.1016/j.pnpbp.2026.111627 Full text Depression Ketamine Major depressive disorder Antidepressants +4

Transforming treatment-resistant depression (TRD) care in the Gulf Cooperation Council (GCC) countries: a narrative review of emerging therapies, advancements, and implementation barriers.

Annals of General Psychiatry January 21, 2026 Mohammed A Alhassan

Treatment-resistant depression (TRD) remains a major clinical challenge worldwide and across the Gulf Cooperation Council (GCC) countries, where the burden of mental health disorders continues to rise. Conventional TRD therapies, including antidepressants, augmentation strategies, and electroconvulsive therapy (ECT), often result in incomplete remission and are associated with significant...

DOI: 10.1186/s12991-025-00626-1 Full text Esketamine Treatment-resistant depression Antidepressant therapies Gcc mental health +2